Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Quinazoline derivatives for the treatment of cancer diseases
US9089571B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9089571-B2 |
| Application number | US-201313766914-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 14, 2013 |
| Priority date | Nov 11, 2005 |
| Publication date | Jul 28, 2015 |
| Grant date | Jul 28, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of quinazolines of formula (I), wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating head and neck squamous cell carcinoma in a patient, the method comprising administering a therapeutically effective amount of an EGFR inhibitor to the patient wherein said inhibitor is the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline or a physiologically acceptable salt thereof. 2. The method according to claim 1 , wherein the Head and neck squamous cell carcinoma is selected from the group consisting of lip and oral cavity cancer, laryngeal cancer, nasopharyngeal cancer, oropharyngeal cancer and hypopharyngeal cancer. 3. The method according to claim 1 or 2 , wherein the compound is (d′) 4-[3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
- A61K31/517Primary
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title
having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9089571B2 cover?
- The present invention relates to the use of quinazolines of formula (I), wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.
- Who is the assignee on this patent?
- Solca Flavio, Amelsberg Andree, Van Meel Jacobus C A, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/517. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).